Continue Reading
Full article on Yahoo Finance
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
Market Intelligence Analysis
AI-Powered 80% GROQ-LLAMA-3.1-8B-INSTANT
Why This Matters
Adial Pharmaceuticals will implement a 1-for-25 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, with trading adjusted on February 6, 2026.
Market Impact
Market impact analysis based on neutral sentiment with 80% confidence.
Sentiment
Neutral
AI Confidence
80%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (the “Reverse Split”) of its common stock, par value $0.001 per share (“Common Stock”), that
AI Breakdown
Summary
Adial Pharmaceuticals will implement a 1-for-25 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, with trading adjusted on February 6, 2026.
Market Impact
Market impact analysis based on neutral sentiment with 80% confidence.
Time Horizon
Short Term
Original article published by
Yahoo Finance
on February 4, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.